Matsubara, N., Azad, A. A., Agarwal, N., Saad, F., De Giorgi, U., Joung, J. Y., . . . Fizazi, K. (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: Patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The lancet. Oncology, 26(4), . https://doi.org/10.1016/S1470-2045(25)00030-0
Chicago-Zitierstil (17. Ausg.)Matsubara, Nobuaki, et al. "First-line Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide for Metastatic Castration-resistant Prostate Cancer: Patient-reported Outcomes from the Randomised, Double-blind, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet. Oncology 26, no. 4 (2025). https://doi.org/10.1016/S1470-2045(25)00030-0.
MLA-Zitierstil (9. Ausg.)Matsubara, Nobuaki, et al. "First-line Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide for Metastatic Castration-resistant Prostate Cancer: Patient-reported Outcomes from the Randomised, Double-blind, Placebo-controlled, Phase 3 TALAPRO-2 Trial." The Lancet. Oncology, vol. 26, no. 4, 2025, https://doi.org/10.1016/S1470-2045(25)00030-0.